A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer

Preclinical data have demonstrated that the combination of antihuman epidermal growth factor receptor-2 (anti-HER2) and antivascular endothelial growth factor (anti-VEGF)—targeted agents has antitumor activity; these data indicate certain patients with HER2-overexpressing breast cancer may derive cl...

Full description

Saved in:
Bibliographic Details
Main Authors: Rugo, Hope S., Jo Chien, A., Franco, Sandra X., Stopeck, Alison T., Glencer, Alexa, Lahiri, Soumi, Arbushites, Michael C., Scott, Janet, Park, John W., Hudis, Clifford, Nulsen, Ben, Dickler, Maura N.
Format: Artigo
Language:Inglês
Published: Springer US 2011
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3397213/
https://ncbi.nlm.nih.gov/pubmed/22198412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-011-1918-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items